Re: A couple Q2 events for Zenith

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: A couple Q2 events for Zenith

in response to

Re: A couple Q2 events for Zenith

tada

posted on May 10, 2017 11:31AM

Tada,

I was going off of the December 2016 news release regarding initiation of the combo trial. What is your source that dosing started in January and not December. Not a huge deal.... Only a month difference. Just curious for your reference source.